Brokers Offer Predictions for TNGX Q2 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Stock analysts at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for Tango Therapeutics in a research note issued on Monday, June 9th. B. Riley analyst Y. Zhi expects that the company will earn ($0.35) per share for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.33) EPS.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The firm had revenue of $5.39 million during the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.20.

Tango Therapeutics Stock Up 6.0%

Shares of TNGX stock opened at $4.74 on Wednesday. The company has a market capitalization of $513.79 million, a P/E ratio of -4.02 and a beta of 1.24. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $12.02. The firm has a 50-day moving average price of $1.88 and a 200 day moving average price of $2.40.

Institutional Trading of Tango Therapeutics

Several large investors have recently made changes to their positions in TNGX. Congress Asset Management Co. raised its holdings in shares of Tango Therapeutics by 9.0% in the fourth quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock valued at $704,000 after buying an additional 18,919 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Tango Therapeutics in the 4th quarter valued at about $218,000. Charles Schwab Investment Management Inc. raised its stake in shares of Tango Therapeutics by 5.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company’s stock worth $1,586,000 after acquiring an additional 26,192 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $45,000. Finally, Swiss National Bank lifted its position in shares of Tango Therapeutics by 13.1% during the fourth quarter. Swiss National Bank now owns 94,900 shares of the company’s stock worth $293,000 after purchasing an additional 11,000 shares in the last quarter. Institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.